Repare Therapeutics

Repare Therapeutics, Inc. engages in the research, development, and commercialization of precision oncology drugs targeting specific vulnerabilities of tumors in genetically defined patient populations. The company was founded by Daniel Durocher, Agnel Sfeir and Frank Sicheri on September 6, 2016 and is headquartered in Saint-Laurent, Canada.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Repare Therapeutics, Inc. engages in the research, development, and commercialization of precision oncology drugs targeting specific vulnerabilities of tumors in genetically defined patient populations. The company was founded on September 6, 2016 and is headquartered in Saint-Laurent, Canada.

CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics, today announced the presentation of monotherapy dose selection and safety data from its Phase 1/2 TRESR (Treatment Enabled by SNIPRx) clinical trial of RP-3500 at the 2022 ESMO Targeted Anticancer Therapies (TAT) Congres

Repare Therapeutics Presents RP-3500 Dose Selection Phase 1 Monotherapy Safety Data from the Phase 1/2 TRESR Clinical Trial at the 2022 ESMO Targeted Anticancer Therapies Congress

CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics, today reported financial results for the fourth quarter and full year ended December 31, 2021. “We achieved several key milestones in 2021 to advance our innovative, synthetic lethality-based pipeline across multiple cli

Repare Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2021 Financial Results

CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics, today announced that members of its senior management team will participate in two virtual investor conferences in February. Details are as follows: Guggenheim Oncology Conference Date: Thursday, February 10, 2022 Time:

Repare Therapeutics to Participate in Two Upcoming Virtual Investor Conferences

CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics, today provided a corporate update and highlighted key milestones anticipated in 2022. “2021 was a substantial year of progress for Repare. We presented encouraging initial Phase 1 RP-3500 monotherapy data from our Phase

Repare Therapeutics Provides Corporate Update and Highlights Key Milestones Anticipated in 2022

CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced the appointment of Philip Herman as its EVP Commercial & New Product Development. “We are excited to welcome Phil to Repare as we are looking forward to key catalysts for RP-3500 and RP-6306 in 2022. 2022 will be an important year for us as we continue to build Repare into the leading precision oncology compan

Repare Therapeutics Expands Executive Leadership Team with the Appointment of Philip Herman as EVP Commercial & New Product Development

CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics, today announced that Lloyd M. Segal, President and Chief Executive Officer, will present virtually at the 40th Annual J.P. Morgan Healthcare Conference on Wednesday, January 12, 2022 at 3:45 p.m. Eastern Time. A live web

Repare Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference

CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to discover and develop novel therapeutics, today announced the first patient has been dosed in the Company's Phase 1 clinical trial of RP-6306, a first-in-class small molecule candidate targeting PKMYT1, in combination with gemcitabine for the treatment of molecularly select

Repare Therapeutics Doses First Patient in Phase 1 Clinical Trial of RP-6306 in Combination with Gemcitabine for the Treatment of Advanced Solid Tumors

CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics, today announced that each of its: President and Chief Executive Officer, Lloyd Segal; Executive Vice President and Chief Financial Officer, Steve Forte; Executive Vice-President and Chief Scientific Officer, Michael Zind

Repare Therapeutics Insiders Establish New and Modified Automatic Securities Disposition Plans

The shares of Repare Therapeutics Inc (NASDAQ: RPTX) have received a price target of $48 from Stifel. These are the details.

Repare Therapeutics (RPTX) Stock: $48 Price Target From Stifel

Repare Therapeutics Inc. (RPTX) delivered earnings and revenue surprises of -18.57% and 39.00%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Repare Therapeutics Inc. (RPTX) Reports Q3 Loss, Tops Revenue Estimates

CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics, today reported financial results for the third quarter ended September 30, 2021. “We are pleased with the progress we've made this quarter in our Phase 1 part of the RP-3500 program, including the comprehensive safety da

Repare Therapeutics Provides Business Update and Reports Third Quarter 2021 Financial Results

CAMBRIDGE, Mass. & MONTREAL, Québec--(BUSINESS WIRE)--Repare Therapeutics Inc. (Nasdaq: RPTX), a leading precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics, today announced the closing on November 1, 2021 of its upsized underwritten public offering of 4,600,000 common shares at a public offering price of $22.00 per share, which included the exercise in full by the underwriters of their option to purchase up t

Repare Therapeutics Announces Closing of Upsized Offering of Common Shares and Full Exercise of Underwriters' Option to Purchase Additional Shares

CAMBRIDGE, Mass. & MONTREAL, Quebec--(BUSINESS WIRE)--Repare Therapeutics Inc. (Nasdaq: RPTX), a leading precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics, today announced the pricing of an upsized underwritten public offering of 4,000,000 of its common shares at a public offering price of $22.00 per share, for total gross proceeds of $88.0 million, before deducting underwriting commissions and offering expe

Repare Therapeutics Announces Pricing of Upsized Offering of Common Shares

CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Inc. (Nasdaq: RPTX), a leading precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics, today announced the commencement of a proposed underwritten public offering of $75.0 million of its common shares. All common shares to be sold in the proposed offering will be sold by Repare. Repare also intends to grant the underwriters a 30-day option to purch

Repare Therapeutics Announces Proposed Public Offering of Common Shares

CAMBRIDGE, Mass. & MONTREAL, Quebec--(BUSINESS WIRE)--Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced that members of its senior management team will participate in a fireside chat at the H.C. Wainwright 2nd Annual Precision Oncology Conference on Wednesday, October 20, 2021 at 12:30 p.m. Eastern Time. A live webcast of the fireside chat can be accessed in the Investor section of the Company's website at h

Repare Therapeutics to Participate at the H.C. Wainwright 2nd Annual Precision Oncology Conference

Repare Therapeutics Inc (NASDAQ: RPTX) announced the presentation of preliminary Phase 1 monotherapy data from its Phase 1/2 TRESR trial of RP-3500 for solid tumors with specific synthetic-lethal genomic alterations. Data were presented at the AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics.

Repare Therapeutics Reveals Early Efficacy Data From Lead Program In Solid Tumor Setting

CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced the presentation of preliminary Phase 1 monotherapy clinical data from its Phase 1/2 TRESR (Treatment Enabled by SNIPRx) clinical trial of RP-3500, a potent and selective oral small molecule inhibitor of ATR (Ataxia-Telangiectasia and Rad3-related protein kinase) for the treatment of solid tumors with specific syn

Repare Therapeutics Presents Preliminary Phase 1 Monotherapy Clinical Data from the Ongoing First-in-Human Phase 1/2 TRESR Study of RP-3500 in Solid Tumors at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

The stock price of Repare Therapeutics Inc (NASDAQ: RPTX) increased by over 17% during intraday trading today. This is why it happened.

RPTX Stock: Why It Increased By Over 17% Today

CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today issued the following statement concerning the inadvertent issuance of an abstract by the AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics (“ANE Conference”) concerning an upcoming oral presentation of initial monotherapy clinical data from its ongoing Phase 1/2 clinical trial of R

Repare Therapeutics Issues Statement Regarding Inadvertent Issuance of Phase 1/2 TRESR RP-3500 Clinical Trial Abstract by the AACR-NCI-EORTC Virtual International Conference

CAMBRIDGE, Mass. & MONTREAL, Quebec--(BUSINESS WIRE)--Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced that it has been selected for an oral presentation of initial monotherapy clinical data from its ongoing Phase 1/2 clinical trial of RP-3500 and a poster presentation of preclinical data for RP-3500 at the upcoming AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics

Repare Therapeutics to Present Initial Data from the Phase 1/2 TRESR RP-3500 Clinical Trial at AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics

CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced the appointment of Thomas Civik to its Board of Directors and as its Chairman. He replaces Jerel Davis, Ph.D., Managing Director at Versant Ventures, who will remain a member of the Company's Board. “It is my pleasure to welcome Tom to our Board as our new Chairman,” said Repare President and CEO Lloyd M. Segal. “

Repare Therapeutics Appoints Thomas Civik to Its Board and as New Chairman

CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics, today announced that members of its senior management team will participate in a fireside chat at the 19th Annual Morgan Stanley Virtual Global Healthcare Conference on Thursday, September 9 at 2:45 p.m. Eastern Time. A

Repare Therapeutics to Participate at the 19th Annual Morgan Stanley Virtual Global Healthcare Conference

CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics, today reported financial results for the second quarter ended June 30, 2021. “We are pleased to have dosed the first patient in our Phase 1b/2 ATTACC trial of our ATR inhibitor RP-3500 and additional new PARP inhibitor c

Repare Therapeutics Provides Business Update and Reports Second Quarter 2021 Financial Results

Dicerna Pharmaceuticals

Should you follow Cathie Wood's latest genomic revolution investments?

2 Biotech Stocks ARK Invest Bought in June

CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq:RPTX), a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics, today announced that members of its senior management team will participate in a fireside chat at the 42nd Annual Goldman Sachs Virtual Global Healthcare Conference on Wednesday, June 9 at 3:50 p.m. Eastern Time. A live w

News for Repare Therapeutics Stock (RPTX)